Catalyst Pharmaceuticals Revenue vs. Net Income
| CPRX Stock | USD 22.97 0.62 2.77% |
Total Revenue | First Reported 2004-12-31 | Previous Quarter 146.6 M | Current Value 148.4 M | Quarterly Volatility 41.9 M |
For Catalyst Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Catalyst Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Catalyst Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Catalyst Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Catalyst Pharmaceuticals over time as well as its relative position and ranking within its peers.
Catalyst Pharmaceuticals' Revenue Breakdown by Earning Segment
Check out Trending Equities.
Catalyst Pharmaceuticals Revenue Breakdown by Earning Segment
By analyzing Catalyst Pharmaceuticals' earnings estimates, investors can diagnose different trends across Catalyst Pharmaceuticals' analyst sentiment over time as well as compare current estimates against different timeframes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Catalyst Pharmaceuticals. If investors know Catalyst will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Catalyst Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.2 | Earnings Share 1.71 | Revenue Per Share | Quarterly Revenue Growth 0.153 | Return On Assets |
The market value of Catalyst Pharmaceuticals is measured differently than its book value, which is the value of Catalyst that is recorded on the company's balance sheet. Investors also form their own opinion of Catalyst Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Catalyst Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Catalyst Pharmaceuticals' market value can be influenced by many factors that don't directly affect Catalyst Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Catalyst Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Catalyst Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Catalyst Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Catalyst Pharmaceuticals Net Income vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Catalyst Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Catalyst Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Catalyst Pharmaceuticals is rated second in revenue category among its peers. It also is rated second in net income category among its peers making up about 0.33 of Net Income per Revenue. The ratio of Revenue to Net Income for Catalyst Pharmaceuticals is roughly 3.00 . At this time, Catalyst Pharmaceuticals' Total Revenue is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Catalyst Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Catalyst Revenue vs. Competition
Catalyst Pharmaceuticals is rated second in revenue category among its peers. Market size based on revenue of Health Care industry is currently estimated at about 2.04 Billion. Catalyst Pharmaceuticals totals roughly 491.73 Million in revenue claiming about 24% of equities under Health Care industry.
Catalyst Net Income vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Catalyst Pharmaceuticals |
| = | 491.73 M |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Catalyst Pharmaceuticals |
| = | 163.89 M |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Catalyst Net Income Comparison
Catalyst Pharmaceuticals is currently under evaluation in net income category among its peers.
Catalyst Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Catalyst Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Catalyst Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Catalyst Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Catalyst Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 73.6 K | 77.3 K | |
| Operating Income | 224.4 M | 235.6 M | |
| Income Before Tax | 248.7 M | 261.1 M | |
| Net Income | 188.5 M | 197.9 M | |
| Income Tax Expense | 60.2 M | 63.2 M | |
| Total Other Income Expense Net | 24.3 M | 25.5 M | |
| Net Income From Continuing Ops | 188.5 M | 197.9 M | |
| Non Operating Income Net Other | 3.3 M | 3.5 M | |
| Net Income Applicable To Common Shares | 95.5 M | 100.3 M | |
| Interest Income | 1.8 M | 1.9 M | |
| Net Interest Income | 18.5 M | 19.4 M | |
| Change To Netincome | 14.8 M | 15.5 M | |
| Net Income Per Share | 1.25 | 1.31 | |
| Income Quality | 1.32 | 0.77 | |
| Net Income Per E B T | 0.87 | 1.07 |
Catalyst Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Catalyst Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Catalyst Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Catalyst Pharmaceuticals' important profitability drivers and their relationship over time.
Catalyst Pharmaceuticals Earnings Estimation Breakdown
The calculation of Catalyst Pharmaceuticals' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Catalyst Pharmaceuticals is estimated to be 0.5925 with the future projection ranging from a low of 0.53 to a high of 0.6376. Please be aware that this consensus of annual earnings estimates for Catalyst Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.53 Lowest | Expected EPS | 0.64 Highest |
Catalyst Pharmaceuticals Earnings Projection Consensus
Suppose the current estimates of Catalyst Pharmaceuticals' value are higher than the current market price of the Catalyst Pharmaceuticals stock. In this case, investors may conclude that Catalyst Pharmaceuticals is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Catalyst Pharmaceuticals' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2026 | Current EPS (TTM) | |
| 7 | 82.75% | 0.0 | 0.5925 | 1.71 |
Catalyst Pharmaceuticals Earnings per Share Projection vs Actual
Actual Earning per Share of Catalyst Pharmaceuticals refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Catalyst Pharmaceuticals predict the company's earnings will be in the future. The higher the earnings per share of Catalyst Pharmaceuticals, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Catalyst Pharmaceuticals Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Catalyst Pharmaceuticals, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Catalyst Pharmaceuticals should always be considered in relation to other companies to make a more educated investment decision.Catalyst Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Catalyst Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
2025-11-05 | 2025-09-30 | 0.33 | 0.42 | 0.09 | 27 | ||
2025-08-06 | 2025-06-30 | 0.39 | 0.41 | 0.02 | 5 | ||
2025-05-06 | 2025-03-31 | 0.34 | 0.45 | 0.11 | 32 | ||
2025-02-26 | 2024-12-31 | 0.32 | 0.44 | 0.12 | 37 | ||
2024-11-06 | 2024-09-30 | 0.3 | 0.35 | 0.05 | 16 | ||
2024-08-07 | 2024-06-30 | 0.26 | 0.33 | 0.07 | 26 | ||
2024-05-08 | 2024-03-31 | 0.17 | 0.19 | 0.02 | 11 | ||
2024-02-28 | 2023-12-31 | 0.27 | 0.31 | 0.04 | 14 | ||
2023-11-08 | 2023-09-30 | -0.28 | -0.29 | -0.01 | 3 | ||
2023-08-09 | 2023-06-30 | 0.42 | 0.53 | 0.11 | 26 | ||
2023-05-10 | 2023-03-31 | 0.32 | 0.26 | -0.06 | 18 | ||
2023-03-15 | 2022-12-31 | 0.21 | 0.22 | 0.01 | 4 | ||
2022-11-09 | 2022-09-30 | 0.19 | 0.2 | 0.01 | 5 | ||
2022-08-09 | 2022-06-30 | 0.17 | 0.2 | 0.03 | 17 | ||
2022-05-10 | 2022-03-31 | 0.14 | 0.12 | -0.02 | 14 | ||
2022-03-16 | 2021-12-31 | 0.12 | 0.09 | -0.03 | 25 | ||
2021-11-09 | 2021-09-30 | 0.1 | 0.1 | 0.0 | 0 | ||
2021-08-09 | 2021-06-30 | 0.1 | 0.11 | 0.01 | 10 | ||
2021-05-10 | 2021-03-31 | 0.09 | 0.07 | -0.02 | 22 | ||
2021-03-15 | 2020-12-31 | 0.09 | 0.11 | 0.02 | 22 | ||
2020-11-09 | 2020-09-30 | 0.1 | 0.11 | 0.01 | 10 | ||
2020-08-10 | 2020-06-30 | 0.09 | 0.09 | 0.0 | 0 | ||
2020-05-11 | 2020-03-31 | 0.09 | 0.1 | 0.01 | 11 | ||
2020-03-16 | 2019-12-31 | 0.1 | 0.08 | -0.02 | 20 | ||
2019-11-12 | 2019-09-30 | 0.11 | 0.13 | 0.02 | 18 | ||
2019-08-07 | 2019-06-30 | 0.03 | 0.1 | 0.07 | 233 | ||
2019-05-10 | 2019-03-31 | -0.13 | -0.01 | 0.12 | 92 | ||
2019-03-18 | 2018-12-31 | -0.11 | -0.14 | -0.03 | 27 | ||
2018-11-07 | 2018-09-30 | -0.07 | -0.08 | -0.01 | 14 | ||
2018-08-07 | 2018-06-30 | -0.07 | -0.06 | 0.01 | 14 | ||
2018-05-09 | 2018-03-31 | -0.06 | -0.06 | 0.0 | 0 | ||
2018-03-14 | 2017-12-31 | -0.06 | -0.06 | 0.0 | 0 | ||
2017-11-08 | 2017-09-30 | -0.05 | -0.05 | 0.0 | 0 | ||
2017-08-09 | 2017-06-30 | -0.06 | -0.05 | 0.01 | 16 | ||
2017-05-10 | 2017-03-31 | -0.06 | -0.06 | 0.0 | 0 | ||
2017-03-15 | 2016-12-31 | -0.07 | -0.05 | 0.02 | 28 | ||
2016-11-09 | 2016-09-30 | -0.06 | -0.05 | 0.01 | 16 | ||
2016-08-09 | 2016-06-30 | -0.07 | -0.06 | 0.01 | 14 | ||
2016-05-10 | 2016-03-31 | -0.07 | -0.07 | 0.0 | 0 | ||
2016-03-15 | 2015-12-31 | -0.07 | -0.07 | 0.0 | 0 | ||
2015-11-09 | 2015-09-30 | -0.07 | -0.05 | 0.02 | 28 | ||
2015-08-10 | 2015-06-30 | -0.07 | -0.06 | 0.01 | 14 | ||
2015-05-11 | 2015-03-31 | -0.09 | -0.06 | 0.03 | 33 | ||
2015-03-16 | 2014-12-31 | -0.07 | -0.05 | 0.02 | 28 | ||
2014-11-13 | 2014-09-30 | -0.05 | -0.07 | -0.02 | 40 | ||
2014-08-13 | 2014-06-30 | -0.07 | -0.05 | 0.02 | 28 | ||
2014-05-15 | 2014-03-31 | -0.06 | -0.07 | -0.01 | 16 | ||
2014-03-19 | 2013-12-31 | -0.07 | -0.02 | 0.05 | 71 | ||
2013-11-14 | 2013-09-30 | -0.07 | -0.13 | -0.06 | 85 | ||
2013-08-15 | 2013-06-30 | -0.06 | -0.08 | -0.02 | 33 | ||
2013-05-14 | 2013-03-31 | -0.07 | -0.04 | 0.03 | 42 | ||
2012-11-15 | 2012-09-30 | -0.03 | -0.08 | -0.05 | 166 | ||
2012-08-15 | 2012-06-30 | -0.04 | -0.01 | 0.03 | 75 | ||
2012-05-16 | 2012-03-31 | -0.08 | -0.04 | 0.04 | 50 | ||
2011-11-15 | 2011-09-30 | -0.07 | -0.05 | 0.02 | 28 | ||
2011-08-16 | 2011-06-30 | -0.08 | -0.06 | 0.02 | 25 | ||
2011-04-01 | 2011-03-31 | -0.07 | -0.04 | 0.03 | 42 | ||
2011-03-31 | 2010-12-31 | -0.07 | -0.04 | 0.03 | 42 | ||
2010-11-16 | 2010-09-30 | -0.08 | -0.05 | 0.03 | 37 | ||
2010-08-13 | 2010-06-30 | -0.07 | -0.07 | 0.0 | 0 | ||
2010-05-17 | 2010-03-31 | -0.04 | -0.06 | -0.02 | 50 | ||
2010-03-31 | 2009-12-31 | -0.05 | -0.06 | -0.01 | 20 | ||
2009-11-12 | 2009-09-30 | -0.1 | -0.09 | 0.01 | 10 | ||
2009-08-07 | 2009-06-30 | -0.2 | -0.13 | 0.07 | 35 | ||
2009-05-14 | 2009-03-31 | -0.24 | -0.22 | 0.02 | 8 | ||
2009-03-26 | 2008-12-31 | -0.23 | -0.27 | -0.04 | 17 | ||
2008-11-14 | 2008-09-30 | -0.23 | -0.22 | 0.01 | 4 | ||
2008-05-16 | 2008-03-31 | -0.12 | -0.13 | -0.01 | 8 | ||
2008-03-26 | 2007-12-31 | -0.07 | -0.08 | -0.01 | 14 | ||
2007-11-14 | 2007-09-30 | -0.16 | -0.06 | 0.1 | 62 | ||
2007-08-10 | 2007-06-30 | -0.14 | -0.1 | 0.04 | 28 | ||
2007-05-14 | 2007-03-31 | -0.18 | -0.1 | 0.08 | 44 |
Use Catalyst Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Catalyst Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Catalyst Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Catalyst Pharmaceuticals Pair Trading
Catalyst Pharmaceuticals Pair Trading Analysis
The ability to find closely correlated positions to Catalyst Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Catalyst Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Catalyst Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Catalyst Pharmaceuticals to buy it.
The correlation of Catalyst Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Catalyst Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Catalyst Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Catalyst Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Catalyst Pharmaceuticals position
In addition to having Catalyst Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Treasury ETFs Thematic Idea Now
Treasury ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Treasury ETFs theme has 124 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Treasury ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Catalyst Stock Analysis
When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.